IIM
NVO

Ipswich Investment Management’s Novo Nordisk NVO Stock Holding History

Ipswich Investment Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Buy
50,411
+6,870
+16% +$295K 0.51% 49
2026
Q1 		$1.6M Sell
43,541
-30,357
-41% -$1.44M 0.38% 61
2025
Q4 		$3.76M Sell
73,898
-1,097
-1% -$56.1K 0.87% 34
2025
Q3 		$4.16M Sell
74,995
-17
-0% -$995 0.97% 29
2025
Q2 		$5.18M Buy
75,012
+3,187
+4% +$217K 1.25% 25
2025
Q1 		$4.99M Buy
71,825
+2,545
+4% +$210K 1.24% 28
2024
Q4 		$5.96M Sell
69,280
-1,267
-2% -$137K 1.43% 22
2024
Q3 		$8.4M Sell
70,547
-570
-0.8% -$76K 1.95% 14
2024
Q2 		$10.2M Sell
71,117
-1,291
-2% -$171K 2.38% 8
2024
Q1 		$9.3M Sell
72,408
-1,968
-3% -$234K 2.18% 6
2023
Q4 		$7.69M Sell
74,376
-7,394
-9% -$731K 1.95% 9
2023
Q3 		$7.44M Sell
81,770
-10,440
-11% -$920K 2.03% 8
2023
Q2 		$7.46M Sell
92,210
-4,884
-5% -$399K 1.96% 9
2023
Q1 		$7.73M Sell
97,094
-392
-0.4% -$27.8K 2.11% 8
2022
Q4 		$6.6M Sell
97,486
-3,756
-4% -$220K 1.89% 10
2022
Q3 		$5.04M Sell
101,242
-1,732
-2% -$92.8K 1.61% 15
2022
Q2 		$5.74M Sell
102,974
-1,786
-2% -$99.1K 1.65% 13
2022
Q1 		$5.82M Buy
104,760
+1,420
+1% +$72.9K 1.44% 17
2021
Q4 		$5.79M Sell
103,340
-200
-0.2% -$10.8K 1.35% 17
2021
Q3 		$4.97M Sell
103,540
-1,488
-1% -$71.9K 1.27% 19
2021
Q2 		$4.4M Buy
105,028
+12
+0% +$465 1.12% 22
2021
Q1 		$3.54M Buy
105,016
+2,820
+3% +$100K 1% 33
2020
Q4 		$3.57M Buy
102,196
+360
+0.4% +$12.4K 1.07% 32
2020
Q3 		$3.54M Buy
101,836
+65,978
+184% +$2.2M 1.13% 30
2020
Q2 		$1.17M Buy
35,858
+19,000
+113% +$606K 0.4% 63
2020
Q1 		$507K Sell
16,858
-2
-0% -$60 0.2% 103
2019
Q4 		$488K Hold
16,860
– – 0.14% 123
2019
Q3 		$436K Sell
16,860
-200
-1% -$5.06K 0.14% 126
2019
Q2 		$435K Buy
17,060
+100
+0.6% +$2.47K 0.14% 127
2019
Q1 		$444K Sell
16,960
-210
-1% -$5.16K 0.15% 120
2018
Q4 		$396K Buy
17,170
+5,900
+52% +$131K 0.15% 115
2018
Q3 		$266K Buy
+11,270
New +$275K 0.09% 145
2016
Q2 		– Sell
-4,000
Closed -$110K – 264
2016
Q1 		$110K Buy
+4,000
New +$107K 0.05% 166

Other funds holding NVO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ipswich Investment Management's NVO Position: Q2 2026 in Review

Ipswich Investment Management increased its Novo Nordisk (NVO) stake by 16% in Q2 2026, buying an estimated $295K and bringing the position to 50,411 shares worth $2.42M. The position accounts for 0.51% of the portfolio, ranked #49.

Ipswich Investment Management first reported a position in NVO in Q1 2016 and has held it in 33 quarters since. The position peaked at $10.2M in Q2 2024. 328 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Ipswich Investment Management held 50,411 shares of Novo Nordisk worth $2.42M as of Q2 2026.
  • Ipswich Investment Management bought 6,870 Novo Nordisk shares in Q2 2026, an estimated $295K.
  • Novo Nordisk made up 0.51% of Ipswich Investment Management's portfolio in Q2 2026, its #49 holding.
  • Ipswich Investment Management first reported a position in Novo Nordisk in Q1 2016 and has held it in 33 quarters since.
  • Ipswich Investment Management's Novo Nordisk position peaked at $10.2M in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Ipswich Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.